Abstract
Background Stratipath Breast is a CE-IVD marked artificial intelligence-based solution for prognostic risk stratification of breast cancer patients into high- and low-risk groups, using haematoxylin and eosin (H&E)-stained histopathology whole slide images (WSIs). In this validation study, we assess the prognostic performance of Stratipath Breast in independent breast cancer cases.
Methods This is a retrospective multi-site study including patients (N=2475) diagnosed with primary breast cancer at two hospitals in Sweden. The Stratipath Breast tool was applied to stratify patients based on digitised WSIs of the diagnostic H&E-stained tissue sections from surgically resected tumours. The prognostic performance was evaluated using time-to-event analysis by multivariable Cox Proportional Hazards analysis with progression-free survival (PFS) as the primary endpoint.
Results In the clinically relevant oestrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)-patient subgroup, the estimated Hazard Ratio (HR) associated with PFS between low- and high-risk groups was 2.61 (95% CI: 1.50 - 4.50, p < 0.001) after adjusting for established risk factors. In the ER+/HER2-Nottingham histological grade (NHG) 2 (intermediate risk) subgroup, the HR was 1.99 (95% CI: 1.10 - 3.60, p = 0.023) between low- and high-risk groups.
Conclusion The results indicate an independent prognostic value of Stratipath Breast in both the general breast cancer population, in the clinically relevant ER+/HER2-subgroup and in the NHG2/ER+/HER2-subgroup. Improved risk stratification of intermediate-risk ER+/HER2-breast cancers provides information relevant for treatment decisions of adjuvant chemotherapy and has the potential to reduce both under- and over-treatment. Image-based risk stratification provides the added benefit of short lead times and substantially lower cost compared to molecular diagnostics and therefore has the potential to reach broader patient groups.
Competing Interest Statement
JH has obtained speaker's honoraria or advisory board remunerations from Roche, Novartis, AstraZeneca, Pfizer, Eli Lilly, MSD and Gilead, and has received institutional research support from Cepheid, Novartis, Roche and AstraZeneca. MR and JH are co-founders and shareholders of Stratipath AB. SR is an employee at Stratipath AB and holds employee stock options. All other authors have declared no conflicts of interest.
Funding Statement
This work was supported by funding from the Swedish Research Council, Swedish Cancer Society, Karolinska Institutet, ERA PerMed (ERAPERMED2019-224-ABCAP), VINNOVA and SweLIFE (SwAIPP project), MedTechLabs, Swedish e-science Research Centre (SeRC) - eCPC, Stockholm Region, Stockholm Cancer Society and Swedish Breast Cancer Association.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has approval from the Swedish Ethical Review Authority (2017/2106-31, with amendments 2018/1462-32 and 2019-02336).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to update the following: - added bold text formatting to the subheadings in the Abstract - included appropriate information regarding Ethical approvals for this study in the main manuscript
Data Availability
Data cannot be made public due to local legislation since it contains sensitive patient data.
List of abbreviations
- H&E
- Haematoxylin & Eosin
- WSI
- Whole Slide Image
- ER
- Oestrogen Receptor
- HER2
- Human Epidermal Growth Factor Receptor 2
- HR
- Hazard Ratio
- PFS
- Progression-Free Survival
- NHG
- Nottingham Histological Grade
- RS
- Risk Score
- ATAC
- Arimidex, Tamoxifen Alone or in Combination
- ROR
- Risk Of Recurrence
- ABCSG-8
- Austrian Breast and Colorectal Study Group-8
- GGI
- Genomic Grade Index
- AI
- Artificial Intelligence
- KM
- Kaplan-Meier
- IHC
- Immunohistochemistry
- CI
- Confidence Interval
- PH
- Proportional Hazard
